Hikma Eyes Return To Growth After Further Cutting Generics Forecasts
Injectables And Branded Increases Offset 18% Sales Slide For Generics Unit In First Half
Executive Summary
Hikma has once again downgraded its expectations for its generics business in 2022 as it revealed a first-half drop of 18% in sales for the unit. However, injectables and branded increases helped to offset the decline, while the company maintained that generics growth was on the horizon in 2023.
You may also be interested in...
Hikma Manages To Stay Flat In 2022 Despite Generics Pressures
As expected, Hikma’s generics business saw a significant slide in 2022 – but contributions from its successful injectables and brands divisions helped to stop an overall sales decline for the firm.
Hikma Delivers On Authorized Xyrem In US
Hikma has begun 2023 with the long-awaited launch of a US authorized generic version of Xyrem (sodium oxybate). Meanwhile, the company has also struck a deal with Junshi Biosciences for toripalimab in the MENA region.
Hikma Expectations Stabilize – But Generics Still Set To Take A Hit
After multiple cuts to its Generics guidance earlier this year, Hikma has reiterated its expectations for the company’s full-year results, citing momentum for the firm’s Injectables and Branded segments as well as promising that growth is on the horizon for Generics in 2023.